Cargando…
Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients
Background: Chest Computed Tomography (CT) imaging has played a central role in the diagnosis of interstitial pneumonia in patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be used to obtain the extent of lung involvement in COVID-19 pneumonia patients either...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222070/ https://www.ncbi.nlm.nih.gov/pubmed/35741310 http://dx.doi.org/10.3390/diagnostics12061501 |
_version_ | 1784732782606417920 |
---|---|
author | Risoli, Camilla Nicolò, Marco Colombi, Davide Moia, Marco Rapacioli, Fausto Anselmi, Pietro Michieletti, Emanuele Ambrosini, Roberta Di Terlizzi, Marco Grazioli, Luigi Colmo, Cristian Di Naro, Angelo Natale, Matteo Pio Tombolesi, Alessandro Adraman, Altin Tuttolomondo, Domenico Costantino, Cosimo Vetti, Elisa Martini, Chiara |
author_facet | Risoli, Camilla Nicolò, Marco Colombi, Davide Moia, Marco Rapacioli, Fausto Anselmi, Pietro Michieletti, Emanuele Ambrosini, Roberta Di Terlizzi, Marco Grazioli, Luigi Colmo, Cristian Di Naro, Angelo Natale, Matteo Pio Tombolesi, Alessandro Adraman, Altin Tuttolomondo, Domenico Costantino, Cosimo Vetti, Elisa Martini, Chiara |
author_sort | Risoli, Camilla |
collection | PubMed |
description | Background: Chest Computed Tomography (CT) imaging has played a central role in the diagnosis of interstitial pneumonia in patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be used to obtain the extent of lung involvement in COVID-19 pneumonia patients either qualitatively, via visual inspection, or quantitatively, via AI-based software. This study aims to compare the qualitative/quantitative pathological lung extension data on COVID-19 patients. Secondly, the quantitative data obtained were compared to verify their concordance since they were derived from three different lung segmentation software. Methods: This double-center study includes a total of 120 COVID-19 patients (60 from each center) with positive reverse-transcription polymerase chain reaction (RT-PCR) who underwent a chest CT scan from November 2020 to February 2021. CT scans were analyzed retrospectively and independently in each center. Specifically, CT images were examined manually by two different and experienced radiologists for each center, providing the qualitative extent score of lung involvement, whereas the quantitative analysis was performed by one trained radiographer for each center using three different software: 3DSlicer, CT Lung Density Analysis, and CT Pulmo 3D. Results: The agreement between radiologists for visual estimation of pneumonia at CT can be defined as good (ICC 0.79, 95% CI 0.73–0.84). The statistical tests show that 3DSlicer overestimates the measures assessed; however, ICC index returns a value of 0.92 (CI 0.90–0.94), indicating excellent reliability within the three software employed. ICC was also performed between each single software and the median of the visual score provided by the radiologists. This statistical analysis underlines that the best agreement is between 3D Slicer “LungCTAnalyzer” and the median of the visual score (0.75 with a CI 0.67–82 and with a median value of 22% of disease extension for the software and 25% for the visual values). Conclusions: This study provides for the first time a direct comparison between the actual gold standard, which is represented by the qualitative information described by radiologists, and novel quantitative AI-based techniques, here represented by three different commonly used lung segmentation software, underlying the importance of these specific values that in the future could be implemented as consistent prognostic and clinical course parameters. |
format | Online Article Text |
id | pubmed-9222070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92220702022-06-24 Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients Risoli, Camilla Nicolò, Marco Colombi, Davide Moia, Marco Rapacioli, Fausto Anselmi, Pietro Michieletti, Emanuele Ambrosini, Roberta Di Terlizzi, Marco Grazioli, Luigi Colmo, Cristian Di Naro, Angelo Natale, Matteo Pio Tombolesi, Alessandro Adraman, Altin Tuttolomondo, Domenico Costantino, Cosimo Vetti, Elisa Martini, Chiara Diagnostics (Basel) Article Background: Chest Computed Tomography (CT) imaging has played a central role in the diagnosis of interstitial pneumonia in patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be used to obtain the extent of lung involvement in COVID-19 pneumonia patients either qualitatively, via visual inspection, or quantitatively, via AI-based software. This study aims to compare the qualitative/quantitative pathological lung extension data on COVID-19 patients. Secondly, the quantitative data obtained were compared to verify their concordance since they were derived from three different lung segmentation software. Methods: This double-center study includes a total of 120 COVID-19 patients (60 from each center) with positive reverse-transcription polymerase chain reaction (RT-PCR) who underwent a chest CT scan from November 2020 to February 2021. CT scans were analyzed retrospectively and independently in each center. Specifically, CT images were examined manually by two different and experienced radiologists for each center, providing the qualitative extent score of lung involvement, whereas the quantitative analysis was performed by one trained radiographer for each center using three different software: 3DSlicer, CT Lung Density Analysis, and CT Pulmo 3D. Results: The agreement between radiologists for visual estimation of pneumonia at CT can be defined as good (ICC 0.79, 95% CI 0.73–0.84). The statistical tests show that 3DSlicer overestimates the measures assessed; however, ICC index returns a value of 0.92 (CI 0.90–0.94), indicating excellent reliability within the three software employed. ICC was also performed between each single software and the median of the visual score provided by the radiologists. This statistical analysis underlines that the best agreement is between 3D Slicer “LungCTAnalyzer” and the median of the visual score (0.75 with a CI 0.67–82 and with a median value of 22% of disease extension for the software and 25% for the visual values). Conclusions: This study provides for the first time a direct comparison between the actual gold standard, which is represented by the qualitative information described by radiologists, and novel quantitative AI-based techniques, here represented by three different commonly used lung segmentation software, underlying the importance of these specific values that in the future could be implemented as consistent prognostic and clinical course parameters. MDPI 2022-06-20 /pmc/articles/PMC9222070/ /pubmed/35741310 http://dx.doi.org/10.3390/diagnostics12061501 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Risoli, Camilla Nicolò, Marco Colombi, Davide Moia, Marco Rapacioli, Fausto Anselmi, Pietro Michieletti, Emanuele Ambrosini, Roberta Di Terlizzi, Marco Grazioli, Luigi Colmo, Cristian Di Naro, Angelo Natale, Matteo Pio Tombolesi, Alessandro Adraman, Altin Tuttolomondo, Domenico Costantino, Cosimo Vetti, Elisa Martini, Chiara Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients |
title | Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients |
title_full | Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients |
title_fullStr | Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients |
title_full_unstemmed | Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients |
title_short | Different Lung Parenchyma Quantification Using Dissimilar Segmentation Software: A Multi-Center Study for COVID-19 Patients |
title_sort | different lung parenchyma quantification using dissimilar segmentation software: a multi-center study for covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222070/ https://www.ncbi.nlm.nih.gov/pubmed/35741310 http://dx.doi.org/10.3390/diagnostics12061501 |
work_keys_str_mv | AT risolicamilla differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT nicolomarco differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT colombidavide differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT moiamarco differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT rapaciolifausto differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT anselmipietro differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT michielettiemanuele differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT ambrosiniroberta differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT diterlizzimarco differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT grazioliluigi differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT colmocristian differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT dinaroangelo differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT natalematteopio differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT tombolesialessandro differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT adramanaltin differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT tuttolomondodomenico differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT costantinocosimo differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT vettielisa differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients AT martinichiara differentlungparenchymaquantificationusingdissimilarsegmentationsoftwareamulticenterstudyforcovid19patients |